Climb Bio (CLYM) director sells 100,000 shares in planned trades

Rhea-AI Filing Summary

Climb Bio, Inc. director Thomas Stephen Basil reported selling a total of 100,000 shares of common stock in open-market transactions on February 12 and 13, 2026. He sold 90,000 shares at a weighted average price of $5.2332 on February 12 and 10,000 shares at a weighted average price of $5.8141 on February 13.

After these sales, Basil directly beneficially owns 204,657 shares of Climb Bio common stock. The filing states the trades were made under a Rule 10b5-1 trading plan adopted on October 14, 2025, and notes that each reported price reflects a weighted average of multiple individual trades within the disclosed price ranges.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

X

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Thomas Stephen Basil

(Last) (First) (Middle)

C/O CLIMB BIO, INC.

20 WILLIAM STREET, SUITE 145

(Street)

WELLESLEY HILLS MA 02481

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Climb Bio, Inc. [ CLYM ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

3. Date of Earliest Transaction (Month/Day/Year)
02/12/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	02/12/2026		S(1)		90,000	D	$5.2332(2)	214,657	D
Common Stock	02/13/2026		S(1)		10,000	D	$5.8141(3)	204,657	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. These transactions were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on October 14, 2025.

2. The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $5.2212 to $5.2481, inclusive. The reporting person undertakes to provide the staff of the Securities and Exchange Commission, the issuer or any security holder of the issuer, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (2) and (3) of this Form 4.

3. The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $5.6200 to $6.1200, inclusive.

	/s/ Chandra Adams, as Attorney-in-Fact	02/17/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider transactions did Climb Bio (CLYM) disclose in this Form 4?

Climb Bio disclosed that director Thomas Stephen Basil sold a total of 100,000 common shares in the open market on February 12–13, 2026. The sales were executed under a pre-arranged Rule 10b5-1 trading plan adopted in October 2025.

How many Climb Bio (CLYM) shares did the director sell and on which dates?

Director Thomas Stephen Basil sold 90,000 shares of Climb Bio common stock on February 12, 2026 and an additional 10,000 shares on February 13, 2026. Together, the transactions total 100,000 shares sold in open-market trades.

At what prices were the Climb Bio (CLYM) insider sales executed?

The filing reports weighted average prices. On February 12, 2026, 90,000 shares were sold at $5.2332, with individual trades between $5.2212 and $5.2481. On February 13, 10,000 shares were sold at $5.8141, within a range of $5.6200 to $6.1200.

How many Climb Bio (CLYM) shares does the reporting director own after these sales?

After completing the reported transactions, director Thomas Stephen Basil directly beneficially owns 204,657 shares of Climb Bio common stock. This post-transaction ownership figure reflects his remaining direct holdings following the 100,000 shares sold on February 12 and 13, 2026.

Were the Climb Bio (CLYM) insider sales part of a Rule 10b5-1 trading plan?

Yes. The Form 4 states the transactions were made under a Rule 10b5-1 trading plan adopted by Thomas Stephen Basil on October 14, 2025. Such plans allow pre-scheduled trading, helping insiders sell shares according to preset instructions over time.

Were the Climb Bio (CLYM) shares sold directly or through an indirect entity?

The filing identifies the ownership as direct, meaning the reported common shares are held directly by Thomas Stephen Basil. There is no indication in the provided content of indirect ownership through a trust, partnership, or other affiliated entity for these transactions.